Moderna just surged 8% on a morning when its closest cancer-vaccine peer barely budged and its own pipeline partner slipped into the red, and no announcement, trial readout, or analyst call explains…
Eli Lilly just crossed the trillion-dollar threshold on the back of a GLP-1 empire growing at nearly 50% annually, but a recent pullback and rising risks are forcing investors to decide whether…
Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are building a separate case altogether for investors willing to look past…
GSK just handed Moderna's biggest rival program a late-stage green light, yet traders are sending MRNA stock sharply higher. The logic behind that reaction tells you something important about where the real…
SCHD just delivered a return most dividend investors spend a decade waiting for, and that success created a problem nobody predicted. Whether fresh money belongs in the fund right now depends on…
Moderna stock shed 7% on Wednesday with no company news to blame, reopening a brutal question that its 439% year-to-date rally had been drowning out: what exactly does a $59 billion valuation…
Merck stock sits near analyst targets that fall short of $200, yet a compressed fall calendar of FDA decisions and a pivotal cancer vaccine readout could force Wall Street to rethink the…
Moderna just posted an 11% surge with zero news behind it, while its longtime mRNA peer BioNTech can barely keep pace with the broader biotech sector. Something broke between these two names,…
Jim Cramer declared the data center trade dead on live television and named the stocks he wants instead, but the rotation he described carries a flaw that Wall Street is quietly ignoring.
Merck and Moderna just proved their cancer vaccine works, and the ripple effects reach far beyond either company. Five names stand to collect a toll on every single dose manufactured, but not…
Eli Lilly just crossed a $1 trillion market cap for the first time, and management is already pointing toward a milestone that would rewrite the drugmaker's history. Whether three converging pipeline catalysts…
Moderna just handed back 7% of its staggering year-to-date run in a single session, and the question rattling traders is whether this is a routine exhale or the beginning of a painful…
Pfizer shares sit near a 52-week high after years of post-pandemic punishment, and now Wall Street analysts are quietly shifting their tone. Here is what the pipeline, the dividend, and the valuation…
A top Barclays biopharma analyst says the forces that froze biotech dealmaking are breaking apart, and the pharma giants shopping for acquisitions have very specific reasons they cannot afford to stop.
JEPI's 8% monthly yield looks like an obvious win over SCHD's modest payout, but the IRS treats those two income streams in ways that can quietly flip the comparison depending on where…
